MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions

MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-breaking abstracts for presentation. The company focuses on developing promising treatments, particularly with its candidate DA-1726, a novel dual oxyntomodulin analog targeting GLP-1 and glucagon receptors, designed to help tackle obesity. The leadership at MetaVia, including President and CEO Hyung Heon Kim, expresses confidence in their cardiometabolic portfolio, particularly as DA-1726 undergoes a Phase 1 Part 3 titration study expected to enhance tolerability at therapeutic doses, with results anticipated in Q4 2026.

Highlighting Key Research and Innovations

The first of the accepted abstracts highlights the safety and pharmacokinetics of DA-1726, presented by researcher Weikai 'Chris' Fang. This presentation aims to provide deeper insights into the efficacy of the drug and its application in clinical settings. Another abstract, led by Tae Hyoung Kim, investigates the effects of vanoglipel—a GPR119 agonist—when combined with Resmetirom in a diet-induced obese mouse model that simulates metabolic dysfunction-associated steatohepatitis (MASH). This study is crucial as it explores potential treatments for liver-related metabolic diseases.

Commitment to Cardiometabolic Health

Meanwhile, a third study led by Yuna Chae focuses on the combined effects of vanoglipel and Metformin on glycemic control and weight reduction, which are critical parameters for managing diabetes effectively. These presentations mark a significant milestone for MetaVia, demonstrating the company's commitment to advancing research in the field of cardiometabolic treatments.

Looking Ahead to ADA 2026

As the ADA Scientific Sessions approach, the anticipation for the insights these presentations will generate continues to grow, positioning MetaVia as a pivotal player in managing conditions such as obesity and metabolic diseases with innovative therapeutic approaches. All three posters will be publicly available on MetaVia’s website after the presentations, allowing greater access to their research findings.